Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., a leading innovator in cyclodextrin technology and applications, is pleased to announce its participation in the upcoming China International Cosmetics and Personal Care Ingredients Exhibition (PCHi 2026). The event will take place from March 18 to 20, 2026, at the Hangzhou Convention and Exhibition Center.
Under the theme “Focusing on Cyclodextrin Encapsulation, Providing Customized Services,” Zhiyuan Biotechnology will welcome visitors at Booth 3C55 in Hall 3. The company will present its latest advancements in cyclodextrin technology, demonstrating how its innovative solutions address key challenges in cosmetic and personal care formulations. By offering efficient, safe, and high-performance raw material solutions, Zhiyuan aims to empower global customers with cutting-edge ingredients that enhance product efficacy and consumer experience.
Key Product Highlights at PCHi 2026:
65% Water-Soluble Azelaic Acid:
This innovative product significantly improves the solubility of azelaic acid in water while maintaining its full efficacy. It enables controlled slow release to prolong the active effect and effectively regulates local concentration, resulting in reduced skin irritation.
40% Water-Soluble Salicylic Acid:
Designed to enhance the solubility of salicylic acid in aqueous systems, this technology regulates the release rate and controls the local concentration on the skin surface. It ensures effective concentration levels while minimizing potential irritation.
Hyperbranched Cyclodextrin:
Offering highly effective encapsulation and protection for multiple active ingredients, hyperbranched cyclodextrin improves formulation stability and enhances hydrophilicity for better dispersion across various dosage forms. It enables precise regulation through sustained release and targeted delivery capabilities.
Hydroxypropyl Cyclodextrin:
This versatile derivative improves the solubility of poorly soluble raw materials, reduces irritation caused by organic molecules, and enhances overall formulation stability. It also regulates the release rate of active ingredients while effectively masking undesirable odors. In addition to these cyclodextrin-based innovations, Zhiyuan Biotechnology will showcase hydroxypropyl deacetylated chitosan and other cyclodextrin derivatives. These products demonstrate significant advantages in regulating local concentration, reducing irritation, improving formulation stability, and achieving sustained and controlled release.
Exhibition Details: Dates: March 18–20, 2026
Venue: Hangzhou Convention and Exhibition Center (Nanyang Street, Xiaoshan District, Hangzhou City, Zhejiang Province)
Booth Number: 3C55
BINZHOU, China – March 2026 –
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., a dedicated specialist in the field of functional excipients, is proud to announce a significant breakthrough in its corporate development. The company has successfully obtained the Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) for its Betadex Sulfobutyl Ether Sodium product. This prestigious certification marks a new chapter for the company, affirming its technical expertise and opening doors to international markets.
Since its inception, Binzhou Zhiyuan Biotechnology has recognized the immense potential of cyclodextrin. As a functional excipient characterized by its unique cyclic molecular structure, cyclodextrin plays a vital role across numerous sectors, including pharmaceuticals, food, daily chemicals, and agriculture, owing to its exceptional solubilizing, encapsulating, and stabilizing properties. Committing itself to this niche market, the company has evolved from small-batch trial productions to operating a state-of-the-art production facility equipped with advanced machinery and a comprehensive quality control system. This journey of growth has been fueled by the ingenuity of its R&D team and the dedication of its production staff.
For sixteen years, the company has maintained a meticulous focus on process research and development. Significant human, material, and financial resources have been consistently invested in process optimization and technological innovation. The R&D team has conducted in-depth studies on the molecular structure and reaction mechanisms of cyclodextrin to continuously refine production parameters. Every step of the process—from raw material selection and fermentation preparation to separation, purification, and final product testing—has been repeatedly optimized. Through a strategy combining independent research with technology introduction, Binzhou Zhiyuan has successfully overcome numerous technical challenges. These efforts have resulted in significantly improved product purity and yield, reduced production costs, and a minimized environmental footprint.
Betadex Sulfobutyl Ether Sodium (SBECD) is a novel solubilizer and stabilizer widely used in injectable formulations of poorly soluble drugs, including critical medications such as remdesivir, voriconazole, and aripiprazole. The acquisition of the CEP certificate for this key product is not only an authoritative endorsement of Binzhou Zhiyuan’s R&D capabilities and stringent production quality systems but also establishes a new trajectory for the company’s leapfrog development in the global pharmaceutical excipient market. This achievement positions Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. for continued growth and innovation as it strives to provide high-quality solutions to its customers worldwide.
The CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen) will grandly open from September 1 to 3, 2025, at the Shenzhen Convention and Exhibition Center (Futian). The CPHI Shenzhen exhibition will fully stimulate the internal drive and innovative vitality of pharmaceutical enterprises, inject strong development momentum into the global pharmaceutical value chain, and jointly explore new growth opportunities for the pharmaceutical industry in the Greater Bay Area and Asia.
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd., along with its subsidiary Jinan Xinzhiyuan Biotechnology Co., Ltd., will appear at the CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen) held at the Shenzhen Convention and Exhibition Center (Futian) from September 1 to 3, 2025, at Booth 9i28. They will prominently launch new products: “Hydroxypropyl Chitosan” and “Carboxymethyl Chitosan.” This participation aims to deepen industry collaboration and promote the innovative application of cyclodextrin derivatives and chitosan derivatives in fields such as pharmaceuticals and daily chemicals.
Zhiyuan Biotechnology looks forward to exchanging and collaborating with more industry peers to jointly advance innovation and development in the pharmaceutical industry. We believe that through this exhibition, Zhiyuan Biotechnology will be able to establish connections with more industry colleagues and collectively drive the prosperous development of the pharmaceutical sector. At the same time, we also look forward to meeting friends at the exhibition to discuss cooperation and create a brilliant future together!
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd focuses on pharmaceutical&cosmetic raw materials. Equipped with an international R&D team and a stringent quality system. We will participate in In-cosmetics Korea 2025.
Exhibitor: Shandong Binzhou Zhiyuan Biotechnology Co., Ltd
Booth No.: B45
Name: In cosmetics Korea 2025
Time: 2-4 July , 2025
Location: COEX Convention Center, Seoul, Korea
Our exhibited products
Hydroxypropyl Chitosan、Hydroxypropyl betadex 、Methyl beta cyclodextrin、40% Water-soluble Salicylic acid、60% Water-soluble Azelaic acid, etc.
We sincerely invite you to visit our Boss No.: B45 to to explore cooperation opportunities
Contact:
info@cydextrin.com
Phone:86-543-2616568 86-531-61303628
Website: www.cydextrins.com
Highly soluble cocrystals can be used to improve bioavailability of a poorly soluble drug, through generating supersaturation, when absorption is limited by drug dissolution. Dihydromyricetin (DMY) is a biopharmaceutics classification system (BCS) IV drug, exhibiting dissolution limited absorption.
Two novel soluble cocrystals of (±)DMY with caffeine and urea, and their physicochemical properties were evaluated for suitability in formulation development. Although having a much higher solubility than (±)DMY, both cocrystals undergo rapid precipitation during dissolution and form the poorly soluble (±)DMY dihydrate in aqueous media. This negates the potential advantage offered by the high solubility of the two cocrystals in enhancing the dissolution rate and in vivo bioavailability. To solve this problem, we have systematically evaluated suitable crystallization inhibitors to maintain the supersaturation generated by cocrystal dissolution over a prolonged period of time. At 37 °C, an approximately 5-fold enhancement in oral bioavailability of (±)DMY was achieved when both cocrystals were dosed with 2.0 mg/mL polyvinylpyrrolidone K30 solution than (±)DMY dihydrate suspended in 0.5 mg/mL carboxymethylcellulose sodium solution. The study demonstrates that the use of a highly soluble cocrystal along with an appropriate crystallization inhibitor is a potentially effective formulation strategy for improving oral bioavailability of poorly soluble BCS IV drugs.
Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.
Hydroxypropyl beta Cyclodextrin is an ideal solubilizer and excipient for injection.
1.Solubilization and solubilization, dissolve insoluble drugs, improve the solubility of Active ingredient of oily drugs, target drug delivery and protect the effectiveness of drug ingredients.
2.Improve the bioavailability of drugs to increase their efficacy or reduce their dosage.
3.Adjust or control the release rate of drugs to reduce drug toxicity and side effects.
4.Cover up bad odors.
Enterovirus D68 (EV-D68) is a member of the Picornavirus family and a causative agent of respiratory diseases in children. The incidence of EV-D68 infection has increased worldwide in recent years. Thus far, there are no approved antiviral agents or vaccines for EV-D68. In the recently published study of Jiang et al. (Jilin University, China) show that 2,6-Di-O-methyl-Beta-cyclodextrin (methyl-β-cyclodextrin), a common drug that disrupts lipid rafts, specifically inhibits EV-D68 infection without producing significant cytotoxicity at virucidal concentrations. The addition of exogenous cholesterol attenuated the anti-EV-D68 activity of 2,6-Di-O-methyl-Beta-cyclodextrin. 2,6-Di-O-methyl-Beta-cyclodextrin treatment had a weak influence on the attachment of viral particles to the cell membrane (RD cells and HeLa cells) but significantly inhibited EV-D68 entry into host cells. It was demonstrated that EV-D68 facilitated the translocation of the viral receptor protein ICAM-5 to membrane rafts in infected cells. The colocalization of viral particles with ICAM-5 in lipid rafts was thoroughly abolished in cells after treatment with 2,6-Di-O-methyl-Beta-cyclodextrin. It was also shown that 2,6-Di-O-methyl-Beta-cyclodextrin inhibited the replication of isolated circulating EV-D68 strains. The anti-EV-D68 activity of 2,6-Di-O-methyl-Beta-cyclodextrin is mainly mediated by modulating host cell resistance to EV-D68 entry but not the direct binding of virions.
In summary, the results demonstrate that 2,6-Di-O-methyl-Beta-cyclodextrin suppresses EV-D68 replication by perturbing the accumulation of virus particles and ICAM-5 in lipid rafts.
2,6-Di-O-methyl-Beta-cyclodextrin
Azelaic acid limited solubility in water and potential instability present challenges in cosmetic formulation. Hydroxypropyl betadex (HPβCD) can form inclusion complexes with hydrophobic molecules wih azelaic acid, Azelaic Acid/Cyclodextrin Complex advantages:
- Cyclodextrins have a hydrophobic cavity in their structure, which can accommodate the hydrophobic moieties of azelaic acid, thereby enhancing its solubility in aqueous solutions. This increased solubility can lead to better bioavailability and efficacy in topical formulations。
- Complexation with cyclodextrins can protect azelaic acid from degradation, particularly from factors such as light, heat, or oxidation. This can help maintain the stability of azelaic acid in formulations, prolonging its shelf-life and effectiveness.
- Cyclodextrin complexes can improve the permeation of azelaic acid through the skin barrier. This can result in better delivery of the active ingredient to the target site, leading to improved therapeutic outcomes.
- Complexation with cyclodextrins may also reduce skin irritation associated with azelaic acid, as it can help in modulating its release profile and minimizing direct contact with the skin.
There are some volatile and low solubility components in spices, which may cause volatilization loss or insufficient solubility during the preparation process, thereby affecting the stability and performance of spices. Cyclodextrin spice inclusion complex functions as follows:
Hydroxypropyl beta cyclodextrin can encapsulate the volatile components in spices within their internal cyclic structure, forming stable inclusion complexes. It can slow down the volatilization rate, prolong the durability of spices, maintain their aroma characteristics. Can improve the solubility in spices, especially those components with low solubility in water.
Cyclodextrin spice inclusion complex can improve the stability of spices and prevent some components from becoming inactive or degraded due to oxidation, light or other environmental factors. Can regulate the release rate of ingredients in spices. Capable of controlling the release characteristics of spices, prolonging aroma duration, or achieving delayed release of spices.
Hydroxypropyl Β-Cyclodextrin spice inclusion complex can improve the stability, solubility, and release characteristics of spices, can enhancespice’s performance and effectiveness.
Niemann–Pick type C (NPC) disease is a fatal hereditary neurodegenerative disorder characterized by a massive accumulation of cholesterol in lysosomes and late endosomes due to a defect in intracellular cholesterol trafficking. Dysfunction in intracellular cholesterol trafficking is responsible for about 50 rare inherited lysosomal storage disorders including NPC. The lysosomal proteins NPC1 and NPC2 play a crucial role in trafficking of cholesterol from late endosomes and lysosomes to other cellular compartments. However, the detailed mechanisms of cholesterol trafficking at the late endosomes/lysosomes (LE/LY) are poorly understood. Studies showed that 2-hydroxypropyl-β-cyclodextrin (HPβCD) alleviates the cholesterol accumulation defect in animal model and has been approved for a phase 2b/3 clinical trial for NPC. HPβCD is known to bind cholesterol; however, the mechanisms how HPβCD mediates the exit of cholesterol from the LE/LY compartments are still unknown. Further, another cyclodextrin (CD) derivative, 2-hydroxypropyl-γ-cyclodextrin (HPγCD), was shown to reduce intracellular cholesterol accumulation in NPC patient cells and NPC mice model. Herein, we identified a number of candidate proteins differentially expressed in NPC patient-derived cells compared to cells derived from a healthy donor using a proteomic approach. Interestingly, both HPβCD and HPγCD treatments modulated the expression of most of these NPC-specific proteins. Data showed that treatment with both CDs induces the expression of the lysosome-associated membrane protein 1 (LAMP-1) in NPC patient-derived cells. Remarkably, LAMP-1 overexpression in HeLa cells rescued U18666A-induced cholesterol accumulation suggesting a role of LAMP-1 in cholesterol trafficking. We propose that HPβCD and HPγCD facilitate cholesterol export from the LE/LY compartments via the LAMP-1 protein, which may play a crucial role in cholesterol trafficking at the LE/LY compartments when there is no functional NPC1 protein. Together, this study uncovers new cellular mechanisms for cholesterol trafficking, which will contribute to development of novel therapeutic approaches for lysosomal storage diseases.
Covering the entire industrial chain of the pharmaceutical industry and promoting industrial innovation and upgrading, CPHI China 2024 is coming soon. Shandong Binzhou Zhiyuan Biotechnology Co., Ltd, as pioneer and expert in the fields of cyclodextrin R&D, manufacturing and supplying, we are eager to display our latest advancements, innovations, and solutions during this prestigious event.
CPHI China 2024 (Shanghai) Exhibition serves as a prime opportunity for us to connect with esteemed professionals, industry leaders, and potential collaborators from across the globe. During the event, we will be presenting a comprehensive overview of our cutting-edge technologies, product portfolio, and customized solutions tailored to meet the diverse needs of our clients.
Highlights of our showcase include:
- Betadex sulfobutyl ether sodium DMF NO.: 030167
- Hydroxypropyl betadex DMF NO.: 030168
- Hydroxypropyl gamma cyclodextrin DMF NO.: 037142
- Methyl beta cyclodextrin CDE NO.: F20210000272
Cyclodextrin inclusion customization
We are delighted to extend our warmest invitation to you as below:
Date: 19th – 21th June
Venue: Shanghai New International Expo Centre
Booth NO.: E3Q08
Pls contact mail: info@cydextrin.com or Tel: 86 543 2616568
